Actinium Pharmaceuticals, Inc. (ATNM)

No Data available this quarter, please select a different quarter.

EBIT growth above 1.5x TRVN's 14.24%. David Dodd would confirm if core operations or niche positioning yield superior profitability.

Operating income growth above 1.5x TRVN's 14.24%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.

Positive net income growth while TRVN is negative. John Neff might see a big relative performance advantage.

Positive EPS growth while TRVN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.

Positive diluted EPS growth while TRVN is negative. John Neff might view this as a strong relative advantage in controlling dilution.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

OCF growth above 1.5x TRVN's 37.31%. David Dodd would confirm a clear edge in underlying cash generation.

FCF growth above 1.5x TRVN's 37.31%. David Dodd would verify if the firm’s strategic investments yield superior returns.

10Y OCF/share CAGR above 1.5x TRVN's 49.15%. David Dodd would check if a superior product mix or cost edge drives this outperformance.

Positive OCF/share growth while TRVN is negative. John Neff might see a comparative advantage in operational cash viability.

Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.

Net income/share CAGR above 1.5x TRVN's 60.68% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.

Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.

Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.

Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.

Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

Positive asset growth while TRVN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.

Positive BV/share change while TRVN is negative. John Neff sees a clear edge over a competitor losing equity.

We have some new debt while TRVN reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.

No Data available this quarter, please select a different quarter.

We cut SG&A while TRVN invests at 10.57%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.